MoonLake Immunotherapeutics (MLTX) News
Track canonical SquawkNews coverage tagged to MLTX, MoonLake Immunotherapeutics. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 17 indexed stories across 6 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
Multiple Companies Price Offerings
Several companies announce pricing of various offerings
EQUITY | Aug 11, 2026, 09:30 AM UTC
L
MoonLake Immunotherapeutics' CFO Sells 39K Shares
2026-07-03 10:34:01 ET On June 22, Matthias Bodenstedt, Chief Financial Officer of MoonLake Immunotherapeutics
EQUITY | Jul 03, 2026, 02:34 PM UTC
L
Leerink Partners Maintains Outperform on MoonLake, Raises Price Target to $29
Leerink Partners analyst Thomas Smith maintains MoonLake (NASDAQ: MLTX ) with a Outperform and raises the price target from $24 to $29.
EQUITY | Jul 01, 2026, 01:23 PM UTC
H
HTZ: -21% on Notes Offering
Hertz Global Holdings is down 21% premarket on a proposed offering of $300 million of exchangeable senior first-lien secured PIK notes and $100 million of common stock
EQUITY | Jun 24, 2026, 01:13 PM UTC
M
MLTX Prices $200M Offering
MoonLake Immunotherapeutics announces pricing of upsized $200 million public offering
EQUITY | Jun 24, 2026, 09:14 AM UTC
M
MLTX Prices $200M Offering
MoonLake Immunotherapeutics prices upsized $200M public offering of 9M Class A ordinary shares at $20.00 per share
EQUITY | Jun 24, 2026, 05:51 AM UTC
L
CDNL: Proposes Public Offering
CDNL proposes public offering of common stock
EQUITY | Jun 23, 2026, 09:24 AM UTC
M
CDNL: Proposes Public Offering
CDNL proposes public offering of common stock, among other equity offerings from various companies
EQUITY | Jun 22, 2026, 09:10 PM UTC
M
MLTX: Announces $150M Share Offering
MoonLake Immunotherapeutics announces proposed public offering of $150M of its Class A ordinary shares
EQUITY | Jun 22, 2026, 08:06 PM UTC
M
MLTX Proposes Public Offering
MoonLake Immunotherapeutics announces proposed public offering
EQUITY | Jun 22, 2026, 08:01 PM UTC
H
DFTX +65% on Phase 3 Results
DFTX shares rise 65% on positive topline results from Phase 3 Emerge Study of DT120
EQUITY | Jun 22, 2026, 01:17 PM UTC
H
APGE +45% on Acquisition
AbbVie to acquire Apogee Therapeutics, sending APGE stock up 45% premarket
EQUITY | Jun 22, 2026, 12:21 PM UTC
M
MLTX Reports Sonelokimab Results
MoonLake announces week 52 results of sonelokimab from its phase 3 VELA program in hidradenitis suppurativa
EARNINGS | Jun 22, 2026, 09:26 AM UTC
H
SAGT Surges 76%
Sagtec Global shares rise 75.6% in pre-market trading after issuing financial year 2026 guidance projecting 35% revenue growth
EQUITY | Jun 22, 2026, 09:23 AM UTC
H
MLTX: Reports Phase 3 VELA Results
MoonLake announces Phase 3 VELA program week 52 results showing 67.2% of sonelokimab-treated patients achieving HiSCR75 in moderate-to-severe hidradenitis suppurativa
EARNINGS | Jun 22, 2026, 08:05 AM UTC